Search Results 1831-1840 of 19531 for hemoglobin

1. A Study to Evaluate Cellular Senescence with Senolytics to Improve Skeletal Health in Older Humans - Mayo Clinic

   Subjects who are Type II diabetic and on insulin due to a risk of hypoglycemia. Hemoglobin A1c ≥ 8.0% at screening; Abnormal screening labs (see below):.

2. FAQ - eMERGE Genome Informed Risk Assessment - Mayo Clinic Research

   Clinical risk factors include the most recent hemoglobin A1C, reported physical activity and body mass index (BMI). How does the eMERGE study define 'high ...

3. A Study to Compare the Effectiveness and Safety of Emixustat Hydrochloride with Placebo to Treat Macular Atrophy Secondary to Stargadt Disease - Mayo Clinic

   Impaired hematologic function: hemoglobin < 11 g/dL; neutrophil count < 1.6 × 109/L; or platelet count < 100 × 109/L. Any laboratory screening test that ...

4. Deucravacitinib (BMS-986165) in LPP and FFA - Mayo Clinic

   ... hemoglobin < 10 g/dL (100.0 g/L); total white blood cell count < 3000 cells/μL (< 3.00 x 10^3/μL or < 3.00 billion/L); neutropenia (absolute neutrophil ...

5. RESPONDER-HF Trial - Mayo Clinic

   Anemia with Hemoglobin < 10 g/dl 17. Chronic pulmonary disease requiring continuous home oxygen, OR significant chronic pulmonary disease defined as forced ...

6. Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus - Mayo Clinic

   Hemoglobin < 110 g/L (11 g/dL) for females and < 120 g/L (12 g/dL) for males 9. WBC < LLN 10. Platelet count < 150,000/µL 11. ALP > 2 × ULN 12. Patient ...

7. E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS) - Mayo Clinic

   - Hemoglobin (Hb) >= 9 g/dL without ongoing transfusional support (obtained =< 15 days prior to registration) - Absolute neutrophil count (ANC) >= 1.0 x 10 ...

8. A Study to Evaluate the Safety and Effectiveness of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa Evaluating the Safety and Effectiveness of PF-06650833, PF-06700841, and PF-06826647 in Adults with Moderate-to-Severe Hidradenitis Suppurativa - Mayo Clinic

   Hemoglobin < 9.0 g/dL or hematocrit < 30% (< 0.30 v/v);; Absolute lymphocyte count (ALC) < 1.0 x 109 /L (< 1000/mm^3);; Absolute neutrophil count (ANC) < 1.5 ...

9. Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases - Mayo Clinic

   Hemoglobin ≥ 9 g/dL within 21 days prior to registration. Platelet count ≥ 100,000/ mL within 21 days prior to registration. Bilirubin ≤ 1.5 mg/dL (or ...

10. Study to Evaluate the Safety and Effectiveness of BMS-986036 in Adults with Nonalcoholic Steatophepatitis (NASH) and Stage 3 Liver Fibrosis - Mayo Clinic

    Hemoglobin A1c ≥ 10%;; Fasting TGs > 500 mg/dL;; Estimated Glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2 according to the Modification of Diet in ...